MétaCan
Menu
← Back to cohort
Record W4412416720 · doi:10.1002/alz.70347

Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial

2025· article· en· W4412416720 on OpenAlexaff
Austin McCullough, Charles D. Chen, Brian A. Gordon, Nelly Joseph‐Mathurin, Clifford R. Jack, Robert Koeppe, Russ C. Hornbeck, Deborah Koudelis, Nicole S. McKay, Diana A. Hobbs, Shaney Flores, Sarah Keefe, Neelum T. Aggarwal, Ricardo Allegri, Sarah Berman, Thomas D. Bird, Sandra E. Black, William S. Brooks, Jasmeer P. Chhatwal, Gregory S. Day, Martin R. Farlow, Nick C. Fox, Serge Gauthier, Lawrence S. Honig, Ging‐Yuek Robin Hsiung, Mathias Jucker, Johannes Levin, Mario Masellis, Colin L. Masters, Patricio Chrem Méndez, John M. Ringman, B. Joy Snider, Stephen Salloway, Peter R. Schofield, Hiroyuki Shimada, Kazushi Suzuki, Christopher H. van Dyck, Gregory Klein, David B. Clifford, Carlos Cruchaga, Jason Hassenstab, Li Y, Eric McDade, Susan L. Mills, John C. Morris, Richard J. Perrin, Charlene Supnet, Guoqiao Wang, Chengjie Xiong, Randall J. Bateman, Tammie L.S. Benzinger

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldMedicine
TopicAlzheimer's disease research and treatments
Canadian institutionsUniversity of British ColumbiaMcGill UniversitySunnybrook Health Science Centre
FundersNational Institutes of HealthAvid RadiopharmaceuticalsCerveau TechnologiesBrightFocus FoundationNational Institute on AgingEli Lilly and CompanyGHR FoundationAlzheimer's AssociationFoundation for the National Institutes of Health
KeywordsPositron emission tomographyPittsburgh compound BMedicineNeuroimagingNuclear medicineMagnetic resonance imagingAtrophyStandardized uptake valuePet imagingInternal medicinePsychologyDiseaseAlzheimer's diseaseRadiologyPsychiatry

Abstract

fetched live from OpenAlex

INTRODUCTION: Monoclonal anti-amyloid therapies are now accessible, but how these treatments influence changes within the brain is still not clear. We investigated overall and regional change in amyloid removal, glucose metabolism, and atrophy in trial participants with dominantly inherited Alzheimer's disease (DIAD). METHODS: F]-fluoro-2-deoxyglucose (FDG) PET, and magnetic resonance imaging (MRI). RESULTS: Gantenerumab significantly reduced PiB-PET uptake overall and in most regions and showed no changes in FDG-PET or MRI measures. Drug effects were associated with baseline PiB-PET uptake, and the largest effects occurred in medial regions. DISCUSSION: Treated DIAD participants, and especially those with higher amyloid burden, showed a decrease in PiB-PET uptake, which was more pronounced in the basal ganglia and medial frontal structures. These results may inform patient response and future drug trial design. HIGHLIGHTS: Gantenerumab unevenly decreased Aβ burden as measured by PiB-PET across brain regions. The strongest decrease in PiB-PET uptake was in basal ganglia and medial frontal structures. Variable drug effect on Aβ was partly due to the amount of burden present before treatment. There was no regional effect on FDG-PET metabolism or MRI volumetrics after 4 years.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.003
Threshold uncertainty score0.009

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0010.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.324
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations3
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicAlzheimer's disease research and treatments→French-language works237,207→